nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR7—myenteric nerve plexus—colon cancer	0.0776	0.182	CbGeAlD
Methysergide—HTR7—vein—colon cancer	0.05	0.117	CbGeAlD
Methysergide—HTR2A—myenteric nerve plexus—colon cancer	0.0484	0.113	CbGeAlD
Methysergide—Telangiectasia—Fluorouracil—colon cancer	0.035	0.0624	CcSEcCtD
Methysergide—HTR2A—vein—colon cancer	0.0312	0.0731	CbGeAlD
Methysergide—HTR1B—blood vessel—colon cancer	0.0206	0.0482	CbGeAlD
Methysergide—HTR1D—blood vessel—colon cancer	0.0199	0.0467	CbGeAlD
Methysergide—Telangiectasia—Methotrexate—colon cancer	0.0182	0.0324	CcSEcCtD
Methysergide—HTR7—endothelium—colon cancer	0.0172	0.0403	CbGeAlD
Methysergide—HTR7—blood vessel—colon cancer	0.0159	0.0372	CbGeAlD
Methysergide—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.014	0.025	CcSEcCtD
Methysergide—Heartburn—Fluorouracil—colon cancer	0.012	0.0214	CcSEcCtD
Methysergide—HTR2A—endothelium—colon cancer	0.0107	0.0252	CbGeAlD
Methysergide—HTR2A—blood vessel—colon cancer	0.00989	0.0232	CbGeAlD
Methysergide—SIGMAR1—smooth muscle tissue—colon cancer	0.00871	0.0204	CbGeAlD
Methysergide—HTR2B—smooth muscle tissue—colon cancer	0.00869	0.0204	CbGeAlD
Methysergide—Urine output increased—Vincristine—colon cancer	0.00798	0.0142	CcSEcCtD
Methysergide—HTR7—epithelium—colon cancer	0.00772	0.0181	CbGeAlD
Methysergide—Pleural effusion—Capecitabine—colon cancer	0.00752	0.0134	CcSEcCtD
Methysergide—HTR1A—renal system—colon cancer	0.00749	0.0176	CbGeAlD
Methysergide—HTR7—smooth muscle tissue—colon cancer	0.00744	0.0174	CbGeAlD
Methysergide—Hyperaesthesia—Capecitabine—colon cancer	0.00733	0.0131	CcSEcCtD
Methysergide—Polyuria—Vincristine—colon cancer	0.0073	0.013	CcSEcCtD
Methysergide—Thrombophlebitis—Irinotecan—colon cancer	0.00721	0.0129	CcSEcCtD
Methysergide—HTR7—renal system—colon cancer	0.00716	0.0168	CbGeAlD
Methysergide—Euphoric mood—Fluorouracil—colon cancer	0.00708	0.0126	CcSEcCtD
Methysergide—Thrombophlebitis—Fluorouracil—colon cancer	0.00691	0.0123	CcSEcCtD
Methysergide—HTR2B—digestive system—colon cancer	0.00686	0.0161	CbGeAlD
Methysergide—Pain in extremity—Vincristine—colon cancer	0.00641	0.0114	CcSEcCtD
Methysergide—SIGMAR1—bone marrow—colon cancer	0.00634	0.0149	CbGeAlD
Methysergide—Ergonovine—ABCB1—colon cancer	0.00627	0.475	CrCbGaD
Methysergide—SIGMAR1—vagina—colon cancer	0.00607	0.0142	CbGeAlD
Methysergide—HTR2B—vagina—colon cancer	0.00606	0.0142	CbGeAlD
Methysergide—Ataxia—Vincristine—colon cancer	0.00603	0.0108	CcSEcCtD
Methysergide—HTR2A—embryo—colon cancer	0.0059	0.0138	CbGeAlD
Methysergide—HTR7—digestive system—colon cancer	0.00587	0.0138	CbGeAlD
Methysergide—Orthostatic hypotension—Irinotecan—colon cancer	0.0057	0.0102	CcSEcCtD
Methysergide—Ataxia—Fluorouracil—colon cancer	0.00562	0.01	CcSEcCtD
Methysergide—Pleural effusion—Methotrexate—colon cancer	0.00559	0.00998	CcSEcCtD
Methysergide—Urine output increased—Capecitabine—colon cancer	0.0052	0.00929	CcSEcCtD
Methysergide—Dysuria—Vincristine—colon cancer	0.00518	0.00924	CcSEcCtD
Methysergide—Neutropenia—Vincristine—colon cancer	0.00518	0.00924	CcSEcCtD
Methysergide—SIGMAR1—liver—colon cancer	0.00512	0.012	CbGeAlD
Methysergide—Eosinophilia—Fluorouracil—colon cancer	0.00512	0.00913	CcSEcCtD
Methysergide—Neutropenia—Irinotecan—colon cancer	0.00504	0.009	CcSEcCtD
Methysergide—Weight decreased—Vincristine—colon cancer	0.00501	0.00894	CcSEcCtD
Methysergide—Weight decreased—Irinotecan—colon cancer	0.00488	0.00871	CcSEcCtD
Methysergide—Thrombophlebitis—Capecitabine—colon cancer	0.00483	0.00861	CcSEcCtD
Methysergide—HTR2A—epithelium—colon cancer	0.00481	0.0113	CbGeAlD
Methysergide—Polyuria—Capecitabine—colon cancer	0.00476	0.00849	CcSEcCtD
Methysergide—Oliguria—Methotrexate—colon cancer	0.00465	0.0083	CcSEcCtD
Methysergide—HTR2A—smooth muscle tissue—colon cancer	0.00464	0.0109	CbGeAlD
Methysergide—HTR2A—renal system—colon cancer	0.00447	0.0105	CbGeAlD
Methysergide—HTR7—liver—colon cancer	0.00438	0.0103	CbGeAlD
Methysergide—Pain in extremity—Capecitabine—colon cancer	0.00418	0.00745	CcSEcCtD
Methysergide—Flushing—Irinotecan—colon cancer	0.00401	0.00715	CcSEcCtD
Methysergide—Ataxia—Capecitabine—colon cancer	0.00393	0.00701	CcSEcCtD
Methysergide—SIGMAR1—lymph node—colon cancer	0.00393	0.00921	CbGeAlD
Methysergide—Alopecia—Vincristine—colon cancer	0.00392	0.00699	CcSEcCtD
Methysergide—HTR2B—lymph node—colon cancer	0.00392	0.00919	CbGeAlD
Methysergide—Urine output increased—Methotrexate—colon cancer	0.00387	0.00691	CcSEcCtD
Methysergide—Alopecia—Irinotecan—colon cancer	0.00382	0.00681	CcSEcCtD
Methysergide—Orthostatic hypotension—Capecitabine—colon cancer	0.00382	0.00681	CcSEcCtD
Methysergide—Back pain—Vincristine—colon cancer	0.00373	0.00666	CcSEcCtD
Methysergide—HTR2A—digestive system—colon cancer	0.00366	0.00859	CbGeAlD
Methysergide—Alopecia—Fluorouracil—colon cancer	0.00365	0.00652	CcSEcCtD
Methysergide—Back pain—Irinotecan—colon cancer	0.00364	0.00649	CcSEcCtD
Methysergide—Thrombophlebitis—Methotrexate—colon cancer	0.00359	0.00641	CcSEcCtD
Methysergide—Polyuria—Methotrexate—colon cancer	0.00354	0.00632	CcSEcCtD
Methysergide—Ergotamine—ABCB1—colon cancer	0.00353	0.267	CrCbGaD
Methysergide—Ill-defined disorder—Irinotecan—colon cancer	0.00349	0.00622	CcSEcCtD
Methysergide—Bromocriptine—ABCB1—colon cancer	0.0034	0.258	CrCbGaD
Methysergide—Malaise—Irinotecan—colon cancer	0.00339	0.00605	CcSEcCtD
Methysergide—Dysuria—Capecitabine—colon cancer	0.00338	0.00602	CcSEcCtD
Methysergide—Neutropenia—Capecitabine—colon cancer	0.00338	0.00602	CcSEcCtD
Methysergide—Convulsion—Vincristine—colon cancer	0.00334	0.00597	CcSEcCtD
Methysergide—Myalgia—Vincristine—colon cancer	0.00329	0.00586	CcSEcCtD
Methysergide—Weight increased—Capecitabine—colon cancer	0.00329	0.00586	CcSEcCtD
Methysergide—Weight decreased—Capecitabine—colon cancer	0.00327	0.00583	CcSEcCtD
Methysergide—HTR2A—vagina—colon cancer	0.00323	0.00759	CbGeAlD
Methysergide—Discomfort—Irinotecan—colon cancer	0.00316	0.00564	CcSEcCtD
Methysergide—Oedema—Vincristine—colon cancer	0.00315	0.00562	CcSEcCtD
Methysergide—Convulsion—Fluorouracil—colon cancer	0.00312	0.00557	CcSEcCtD
Methysergide—Thrombocytopenia—Vincristine—colon cancer	0.00308	0.0055	CcSEcCtD
Methysergide—Oedema—Irinotecan—colon cancer	0.00307	0.00547	CcSEcCtD
Methysergide—Chest pain—Fluorouracil—colon cancer	0.00307	0.00547	CcSEcCtD
Methysergide—Myalgia—Fluorouracil—colon cancer	0.00307	0.00547	CcSEcCtD
Methysergide—Discomfort—Fluorouracil—colon cancer	0.00303	0.0054	CcSEcCtD
Methysergide—Thrombocytopenia—Irinotecan—colon cancer	0.003	0.00536	CcSEcCtD
Methysergide—Oedema—Fluorouracil—colon cancer	0.00294	0.00524	CcSEcCtD
Methysergide—Ataxia—Methotrexate—colon cancer	0.00292	0.00522	CcSEcCtD
Methysergide—Thrombocytopenia—Fluorouracil—colon cancer	0.00288	0.00513	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00287	0.00512	CcSEcCtD
Methysergide—Tachycardia—Fluorouracil—colon cancer	0.00287	0.00512	CcSEcCtD
Methysergide—Insomnia—Vincristine—colon cancer	0.00285	0.00508	CcSEcCtD
Methysergide—Oedema peripheral—Capecitabine—colon cancer	0.00285	0.00508	CcSEcCtD
Methysergide—Paraesthesia—Vincristine—colon cancer	0.00283	0.00505	CcSEcCtD
Methysergide—Insomnia—Irinotecan—colon cancer	0.00277	0.00495	CcSEcCtD
Methysergide—Paraesthesia—Irinotecan—colon cancer	0.00275	0.00492	CcSEcCtD
Methysergide—Dyspnoea—Irinotecan—colon cancer	0.00274	0.00488	CcSEcCtD
Methysergide—HTR2A—liver—colon cancer	0.00273	0.0064	CbGeAlD
Methysergide—Somnolence—Irinotecan—colon cancer	0.00273	0.00487	CcSEcCtD
Methysergide—Gastrointestinal disorder—Vincristine—colon cancer	0.00272	0.00485	CcSEcCtD
Methysergide—Fatigue—Vincristine—colon cancer	0.00272	0.00485	CcSEcCtD
Methysergide—Dyspepsia—Irinotecan—colon cancer	0.0027	0.00482	CcSEcCtD
Methysergide—Constipation—Vincristine—colon cancer	0.00269	0.00481	CcSEcCtD
Methysergide—Pain—Vincristine—colon cancer	0.00269	0.00481	CcSEcCtD
Methysergide—Flushing—Capecitabine—colon cancer	0.00268	0.00479	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00268	0.00478	CcSEcCtD
Methysergide—Eosinophilia—Methotrexate—colon cancer	0.00266	0.00475	CcSEcCtD
Methysergide—Insomnia—Fluorouracil—colon cancer	0.00266	0.00474	CcSEcCtD
Methysergide—Gastrointestinal disorder—Irinotecan—colon cancer	0.00265	0.00473	CcSEcCtD
Methysergide—Fatigue—Irinotecan—colon cancer	0.00265	0.00472	CcSEcCtD
Methysergide—Paraesthesia—Fluorouracil—colon cancer	0.00264	0.00471	CcSEcCtD
Methysergide—Pain—Irinotecan—colon cancer	0.00262	0.00468	CcSEcCtD
Methysergide—Constipation—Irinotecan—colon cancer	0.00262	0.00468	CcSEcCtD
Methysergide—Dyspnoea—Fluorouracil—colon cancer	0.00262	0.00467	CcSEcCtD
Methysergide—Somnolence—Fluorouracil—colon cancer	0.00261	0.00466	CcSEcCtD
Methysergide—Dyspepsia—Fluorouracil—colon cancer	0.00259	0.00462	CcSEcCtD
Methysergide—Gastrointestinal pain—Vincristine—colon cancer	0.00258	0.0046	CcSEcCtD
Methysergide—Alopecia—Capecitabine—colon cancer	0.00255	0.00456	CcSEcCtD
Methysergide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00254	0.00453	CcSEcCtD
Methysergide—Feeling abnormal—Irinotecan—colon cancer	0.00253	0.00451	CcSEcCtD
Methysergide—Dysuria—Methotrexate—colon cancer	0.00251	0.00449	CcSEcCtD
Methysergide—Neutropenia—Methotrexate—colon cancer	0.00251	0.00449	CcSEcCtD
Methysergide—Pain—Fluorouracil—colon cancer	0.00251	0.00448	CcSEcCtD
Methysergide—Gastrointestinal pain—Irinotecan—colon cancer	0.00251	0.00448	CcSEcCtD
Methysergide—Body temperature increased—Vincristine—colon cancer	0.00249	0.00444	CcSEcCtD
Methysergide—Abdominal pain—Vincristine—colon cancer	0.00249	0.00444	CcSEcCtD
Methysergide—Back pain—Capecitabine—colon cancer	0.00243	0.00434	CcSEcCtD
Methysergide—Abdominal pain—Irinotecan—colon cancer	0.00243	0.00433	CcSEcCtD
Methysergide—Body temperature increased—Irinotecan—colon cancer	0.00243	0.00433	CcSEcCtD
Methysergide—Feeling abnormal—Fluorouracil—colon cancer	0.00242	0.00432	CcSEcCtD
Methysergide—Drowsiness—Methotrexate—colon cancer	0.0024	0.00428	CcSEcCtD
Methysergide—Ill-defined disorder—Capecitabine—colon cancer	0.00233	0.00417	CcSEcCtD
Methysergide—Body temperature increased—Fluorouracil—colon cancer	0.00232	0.00414	CcSEcCtD
Methysergide—Malaise—Capecitabine—colon cancer	0.00227	0.00405	CcSEcCtD
Methysergide—Asthenia—Vincristine—colon cancer	0.00226	0.00403	CcSEcCtD
Methysergide—Asthenia—Irinotecan—colon cancer	0.0022	0.00393	CcSEcCtD
Methysergide—Diarrhoea—Vincristine—colon cancer	0.00216	0.00385	CcSEcCtD
Methysergide—Chest pain—Capecitabine—colon cancer	0.00214	0.00382	CcSEcCtD
Methysergide—Arthralgia—Capecitabine—colon cancer	0.00214	0.00382	CcSEcCtD
Methysergide—Myalgia—Capecitabine—colon cancer	0.00214	0.00382	CcSEcCtD
Methysergide—Discomfort—Capecitabine—colon cancer	0.00212	0.00378	CcSEcCtD
Methysergide—Diarrhoea—Irinotecan—colon cancer	0.0021	0.00375	CcSEcCtD
Methysergide—Dizziness—Vincristine—colon cancer	0.00208	0.00372	CcSEcCtD
Methysergide—Oedema—Capecitabine—colon cancer	0.00205	0.00366	CcSEcCtD
Methysergide—Dizziness—Irinotecan—colon cancer	0.00203	0.00362	CcSEcCtD
Methysergide—Diarrhoea—Fluorouracil—colon cancer	0.00201	0.00359	CcSEcCtD
Methysergide—Thrombocytopenia—Capecitabine—colon cancer	0.00201	0.00359	CcSEcCtD
Methysergide—Tachycardia—Capecitabine—colon cancer	0.002	0.00358	CcSEcCtD
Methysergide—Vomiting—Vincristine—colon cancer	0.002	0.00357	CcSEcCtD
Methysergide—Rash—Vincristine—colon cancer	0.00199	0.00354	CcSEcCtD
Methysergide—Dermatitis—Vincristine—colon cancer	0.00198	0.00354	CcSEcCtD
Methysergide—Vomiting—Irinotecan—colon cancer	0.00195	0.00348	CcSEcCtD
Methysergide—Dizziness—Fluorouracil—colon cancer	0.00194	0.00347	CcSEcCtD
Methysergide—Rash—Irinotecan—colon cancer	0.00193	0.00345	CcSEcCtD
Methysergide—Dermatitis—Irinotecan—colon cancer	0.00193	0.00345	CcSEcCtD
Methysergide—Alopecia—Methotrexate—colon cancer	0.0019	0.00339	CcSEcCtD
Methysergide—Nausea—Vincristine—colon cancer	0.00187	0.00334	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00187	0.00334	CcSEcCtD
Methysergide—Vomiting—Fluorouracil—colon cancer	0.00187	0.00333	CcSEcCtD
Methysergide—Insomnia—Capecitabine—colon cancer	0.00186	0.00331	CcSEcCtD
Methysergide—Rash—Fluorouracil—colon cancer	0.00185	0.00331	CcSEcCtD
Methysergide—Dermatitis—Fluorouracil—colon cancer	0.00185	0.0033	CcSEcCtD
Methysergide—Paraesthesia—Capecitabine—colon cancer	0.00184	0.00329	CcSEcCtD
Methysergide—Dyspnoea—Capecitabine—colon cancer	0.00183	0.00327	CcSEcCtD
Methysergide—Nausea—Irinotecan—colon cancer	0.00182	0.00325	CcSEcCtD
Methysergide—Back pain—Methotrexate—colon cancer	0.00181	0.00323	CcSEcCtD
Methysergide—Dyspepsia—Capecitabine—colon cancer	0.00181	0.00323	CcSEcCtD
Methysergide—Gastrointestinal disorder—Capecitabine—colon cancer	0.00177	0.00316	CcSEcCtD
Methysergide—Fatigue—Capecitabine—colon cancer	0.00177	0.00316	CcSEcCtD
Methysergide—Pain—Capecitabine—colon cancer	0.00176	0.00313	CcSEcCtD
Methysergide—Constipation—Capecitabine—colon cancer	0.00176	0.00313	CcSEcCtD
Methysergide—Nausea—Fluorouracil—colon cancer	0.00175	0.00311	CcSEcCtD
Methysergide—Ill-defined disorder—Methotrexate—colon cancer	0.00174	0.0031	CcSEcCtD
Methysergide—Feeling abnormal—Capecitabine—colon cancer	0.00169	0.00302	CcSEcCtD
Methysergide—Malaise—Methotrexate—colon cancer	0.00169	0.00301	CcSEcCtD
Methysergide—Gastrointestinal pain—Capecitabine—colon cancer	0.00168	0.003	CcSEcCtD
Methysergide—Abdominal pain—Capecitabine—colon cancer	0.00162	0.0029	CcSEcCtD
Methysergide—Body temperature increased—Capecitabine—colon cancer	0.00162	0.0029	CcSEcCtD
Methysergide—Convulsion—Methotrexate—colon cancer	0.00162	0.0029	CcSEcCtD
Methysergide—Arthralgia—Methotrexate—colon cancer	0.00159	0.00285	CcSEcCtD
Methysergide—Myalgia—Methotrexate—colon cancer	0.00159	0.00285	CcSEcCtD
Methysergide—Chest pain—Methotrexate—colon cancer	0.00159	0.00285	CcSEcCtD
Methysergide—Discomfort—Methotrexate—colon cancer	0.00158	0.00281	CcSEcCtD
Methysergide—Thrombocytopenia—Methotrexate—colon cancer	0.0015	0.00267	CcSEcCtD
Methysergide—Asthenia—Capecitabine—colon cancer	0.00147	0.00263	CcSEcCtD
Methysergide—Diarrhoea—Capecitabine—colon cancer	0.0014	0.00251	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00139	0.00248	CcSEcCtD
Methysergide—Insomnia—Methotrexate—colon cancer	0.00138	0.00247	CcSEcCtD
Methysergide—Paraesthesia—Methotrexate—colon cancer	0.00137	0.00245	CcSEcCtD
Methysergide—Dyspnoea—Methotrexate—colon cancer	0.00136	0.00243	CcSEcCtD
Methysergide—Somnolence—Methotrexate—colon cancer	0.00136	0.00242	CcSEcCtD
Methysergide—Dizziness—Capecitabine—colon cancer	0.00136	0.00242	CcSEcCtD
Methysergide—Dyspepsia—Methotrexate—colon cancer	0.00135	0.0024	CcSEcCtD
Methysergide—Gastrointestinal disorder—Methotrexate—colon cancer	0.00132	0.00235	CcSEcCtD
Methysergide—Fatigue—Methotrexate—colon cancer	0.00132	0.00235	CcSEcCtD
Methysergide—Pain—Methotrexate—colon cancer	0.00131	0.00233	CcSEcCtD
Methysergide—Vomiting—Capecitabine—colon cancer	0.00131	0.00233	CcSEcCtD
Methysergide—Rash—Capecitabine—colon cancer	0.00129	0.00231	CcSEcCtD
Methysergide—Dermatitis—Capecitabine—colon cancer	0.00129	0.00231	CcSEcCtD
Methysergide—Feeling abnormal—Methotrexate—colon cancer	0.00126	0.00225	CcSEcCtD
Methysergide—Gastrointestinal pain—Methotrexate—colon cancer	0.00125	0.00223	CcSEcCtD
Methysergide—Nausea—Capecitabine—colon cancer	0.00122	0.00218	CcSEcCtD
Methysergide—Abdominal pain—Methotrexate—colon cancer	0.00121	0.00216	CcSEcCtD
Methysergide—Body temperature increased—Methotrexate—colon cancer	0.00121	0.00216	CcSEcCtD
Methysergide—Asthenia—Methotrexate—colon cancer	0.0011	0.00196	CcSEcCtD
Methysergide—Diarrhoea—Methotrexate—colon cancer	0.00105	0.00187	CcSEcCtD
Methysergide—Dizziness—Methotrexate—colon cancer	0.00101	0.0018	CcSEcCtD
Methysergide—Vomiting—Methotrexate—colon cancer	0.000972	0.00173	CcSEcCtD
Methysergide—Rash—Methotrexate—colon cancer	0.000964	0.00172	CcSEcCtD
Methysergide—Dermatitis—Methotrexate—colon cancer	0.000963	0.00172	CcSEcCtD
Methysergide—Nausea—Methotrexate—colon cancer	0.000908	0.00162	CcSEcCtD
